Blackbird Critical Metals Corp
LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system for obesity and metabolic disorders. The company was incorporated in 2024 and is based in Vancouver, Canada.
Blackbird Critical Metals Corp (BBCMF) - Net Assets
Latest net assets as of October 2025: $1.49 Million USD
Based on the latest financial reports, Blackbird Critical Metals Corp (BBCMF) has net assets worth $1.49 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.55 Million) and total liabilities ($54.69K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.49 Million |
| % of Total Assets | 96.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 495.1 |
Blackbird Critical Metals Corp - Net Assets Trend (2021–2025)
This chart illustrates how Blackbird Critical Metals Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Blackbird Critical Metals Corp (2021–2025)
The table below shows the annual net assets of Blackbird Critical Metals Corp from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $-82.11K | -197.45% |
| 2024-01-31 | $-27.61K | -100.44% |
| 2023-01-31 | $6.34 Million | +1001.43% |
| 2022-01-31 | $575.47K | +11.76% |
| 2021-01-31 | $514.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Blackbird Critical Metals Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42651200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $369.26K | % |
| Total Equity | $-82.11K | 100.00% |
Blackbird Critical Metals Corp Competitors by Market Cap
The table below lists competitors of Blackbird Critical Metals Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AMEN Properties Inc
PINK:AMEN
|
$4.94 Million |
|
Sumeet Industries Limited
NSE:SUMEETINDS
|
$4.94 Million |
|
PT Minahasa Membangun Hebat Tbk
JK:HBAT
|
$4.94 Million |
|
Dongil Technology Ltd
KQ:032960
|
$4.94 Million |
|
White Energy Company Limited
PINK:WECFF
|
$4.94 Million |
|
Techcential International Ltd
TWO:6616
|
$4.94 Million |
|
ViroGates A/S
CO:VIRO
|
$4.93 Million |
|
GROUNDS R.EST. NA O.N.
F:AMMN
|
$4.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Blackbird Critical Metals Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -27,605 to -82,111, a change of -54,506.
- Net loss of 423,765 reduced equity.
- Share repurchases of 1 reduced equity.
- New share issuances of 377,281 increased equity.
- Other factors decreased equity by 8,021.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-423.76K | -516.09% |
| Share Repurchases | $1.00 | -0.0% |
| Share Issuances | $377.28K | +459.48% |
| Other Changes | $-8.02K | -9.77% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Blackbird Critical Metals Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-01-31 | $0.17 | $0.19 | x |
| 2022-01-31 | $0.21 | $0.19 | x |
| 2023-01-31 | $1.39 | $0.19 | x |
| 2024-01-31 | $0.00 | $0.19 | x |
| 2025-01-31 | $0.00 | $0.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Blackbird Critical Metals Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-9.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -1.07% | 0.00% | 0.00x | 1.01x | $-57.01K |
| 2022 | -16.18% | 0.00% | 0.00x | 1.09x | $-150.67K |
| 2023 | -19.20% | 0.00% | 0.00x | 1.01x | $-1.85 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-415.55K |
Industry Comparison
This section compares Blackbird Critical Metals Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Blackbird Critical Metals Corp (BBCMF) | $1.49 Million | -1.07% | 0.04x | $4.94 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |